Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041546 | 0.88 | DCK (0.42) | PTGDR2MAPTTRPM8KMT2A | |
| SCHEMBL13986201 | 0.88 | L3MBTL1 (0.33) | L3MBTL1PTGDR2GLAHRH3 | |
| SCHEMBL2762937 | 0.88 | HRH3 (0.41) | PTGDR2ALDH1A1MAPTHRH3ALOX5 | |
| SCHEMBL13041483 | 0.88 | PTGDR2 (0.37) | L3MBTL1PTGDR2GLAALDH1A1MAPT | |
| SCHEMBL13041530 | 0.86 | DCK (0.32) | L3MBTL1PTGDR2GLAKMT2A | |
| SCHEMBL13041549 | 0.85 | NPC1 (0.41) | ALDH1A1MAPTKDM4ENPC1RAB9A | |
| SCHEMBL13077790 | 0.85 | L3MBTL1 (0.43) | L3MBTL1PTGDR2GLAALDH1A1MAPT | |
| SCHEMBL13041552 | 0.84 | CDC7 (0.37) | L3MBTL1 | |
| SCHEMBL13041513 | 0.82 | RAB9A (0.36) | L3MBTL1PTGDR2ALDH1A1MAPTNPC1 | |
| SCHEMBL13041547 | 0.82 | PTGDR2 (0.44) | PTGDR2GLAALDH1A1TRPM8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8956999-B2 | Herbicides | SYNGENTA LIMITED (GB) | 2015-02-17 | — | — | US | disclosed |
| US-8956999-B2 | Herbicides | SYNGENTA LIMITED (GB) | 2015-02-17 | — | — | US | disclosed |
| EP-2173727-B1 | NOVEL HERBICIDES | SYNGENTA LTD (GB) | 2013-11-06 | — | — | EP | disclosed |
| US-20100279868-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| WO-2009000533-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279868-A1 | NOVEL HERBICIDES | DDT, HPD, HSD17B1 | L3MBTL1 3731/4885PTGDR2 865/4885GLA 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.